ENANTA PHARMACEUTICALS, INC
Income Statement
| Line Item | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|
| Revenue | $102.8M | $88.3M | $160.9M | $47.7M | $32.1M | $41.7M | $41.9M |
| Cost of Revenue | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — |
| Operating Expenses | |||||||
| Research & Development | $57.5M | $40.5M | $23.2M | $18.7M | $16.8M | $15.1M | $11.5M |
| SG&A Expense | $20.7M | $17.0M | $13.5M | $10.0M | $6.2M | $5.3M | $5.0M |
| Operating Income | $24.6M | $30.8M | $124.1M | $19.0M | $9.0M | $21.3M | $25.3M |
| Operating Margin | 23.9% | 34.9% | 77.2% | 39.8% | 28.2% | 51.0% | 60.4% |
| Interest Expense | $40.0K | $45.0K | $8.0K | $18.0K | $31.0K | — | $3.2M |
| Pretax Income | $26.9M | $32.6M | $125.5M | $19.3M | $9.6M | $21.4M | — |
| Income Tax Expense | $9.2M | $10.9M | $46.5M | $-15.2M | $0 | $0 | $0 |
| Net Income | $17.7M | $21.7M | $79.0M | $34.4M | $9.6M | $21.4M | $23.3M |
| Net Margin | 17.2% | 24.5% | 49.1% | 72.1% | 30.0% | 51.3% | 55.7% |
| EPS (Basic) | $0.93 | $1.14 | $4.23 | $1.88 | $-0.67 | $0.32 | $0.35 |
| EPS (Diluted) | $0.91 | $1.13 | $4.09 | $1.80 | $-0.67 | $0.28 | $0.33 |
| Shares Outstanding (Basic) | 19.1M | 18.9M | 18.7M | 18.4M | 9.8M | 4.4M | 4.5M |
| Shares Outstanding (Diluted) | 19.4M | 19.2M | 19.3M | 19.2M | 9.8M | 9.9M | 7.4M |
| Dividends Per Share | — | — | — | — | — | — | — |